Department of Radiation Oncology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA.
J Urol. 2013 Jul;190(1):97-101. doi: 10.1016/j.juro.2013.01.103. Epub 2013 Feb 8.
National attention has focused on whether urology-radiation oncology practice integration, known as integrated prostate cancer centers, contributes to the use of intensity modulated radiation therapy, a common and expensive prostate cancer treatment.
We examined prostate cancer treatment patterns before and after conversion of a urology practice to an integrated prostate cancer center in July 2006. Using the SEER (Statistics, Epidemiology and End Results)-Medicare database, we identified patients 65 years old or older in 1 statewide registry diagnosed with nonmetastatic prostate cancer between 2004 and 2007. We classified patients into 3 groups, including 1--those seen by integrated prostate cancer center physicians (exposure group), 2--those living in the same hospital referral region who were not seen by integrated prostate cancer center physicians (hospital referral region control group) and 3--those living elsewhere in the state (state control group). We compared changes in treatment among the 3 groups, adjusting for patient, clinical and socioeconomic factors.
Compared with the 8.1 ppt increase in adjusted intensity modulated radiation therapy use in the state control group, the use of this therapy increased 20.3 ppts (95% CI 13.4, 27.1) in the integrated prostate cancer center group and 19.2 ppts (95% CI 9.6, 28.9) in the hospital referral region control group. Androgen deprivation therapy, for which Medicare reimbursement decreased sharply, similarly decreased in integrated prostate cancer center and hospital referral region controls. Prostatectomy decreased significantly in the integrated prostate cancer center group.
Coincident with the conversion of a urology group practice to an integrated prostate cancer center, we observed an increase in intensity modulated radiation therapy and a decrease in androgen deprivation therapy in patients seen by integrated prostate cancer center physicians and those seen in the surrounding health care market that were not observed in the remainder of the state.
全国的注意力都集中在泌尿科 - 放射肿瘤科的实践整合(称为综合前列腺癌中心)是否有助于使用调强放疗,这是一种常见且昂贵的前列腺癌治疗方法。
我们在 2006 年 7 月将泌尿科实践转换为综合前列腺癌中心后,检查了前列腺癌的治疗模式。使用 SEER(统计,流行病学和结果)-医疗保险数据库,我们在全州范围内的 1 个登记处中确定了 2004 年至 2007 年间患有非转移性前列腺癌且年龄在 65 岁或以上的患者。我们将患者分为 3 组,包括 1 - 接受综合前列腺癌中心医生治疗的患者(暴露组),2 - 居住在同一医院转诊区但未接受综合前列腺癌中心医生治疗的患者(医院转诊区对照组)和 3 - 居住在该州其他地方的患者(州对照组)。我们比较了 3 组之间的治疗变化,同时调整了患者、临床和社会经济因素。
与州对照组中调整后调强放疗使用率增加 8.1 个百分点相比,综合前列腺癌中心组的使用率增加了 20.3 个百分点(95%CI 13.4,27.1),医院转诊区对照组的使用率增加了 19.2 个百分点(95%CI 9.6,28.9)。由于医疗保险报销大幅减少,雄激素剥夺疗法也在综合前列腺癌中心和医院转诊区对照组中相应减少。在综合前列腺癌中心组中,前列腺切除术显著减少。
在泌尿科小组实践向综合前列腺癌中心的转换过程中,我们观察到综合前列腺癌中心医生治疗的患者以及周围医疗市场中未观察到的患者中,调强放疗的使用率增加,雄激素剥夺疗法的使用率降低,而在该州其他地区则没有观察到这种情况。